Update publication information In this study, we found that myeloid PTEN can determine chemotherapy responsiveness by promoting NLRP3-dependent antitumor immunity and suggest that it might be a potential biomarker to predict the chemotherapy responses and manipulating NLRP3/IL-1might be able to overcome the chemotherapy resistance in PTEN-loss patients.